Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Piyush Rajbhandari

The Use of Imatinib Resistance Mutation Analysis to Direct Therapy in Philadelphia Chromosome/BCR-Abl1 Positive Chronic Myeloid Leukaemia Patients Failing Imatinib Treatment, in Patan Hospital, Nepal

British Journal of Haematology

Hematology

2017

English

Related publications

Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients

Hematology Reports

Hematology

2012

English

BCR-ABL1 Mutations in Patients With Imatinib-Resistant Philadelphia Chromosome-Positive Leukemia by Use of the PCR-Invader Assay

English

Prognostic Significance of Micro RNA 150 Marker in BCR-ABL Positive Chronic Myeloid Leukaemia Patients on Imatinib Mesylate

International Journal of Contemporary Pediatrics

2017

English

BCR-ABL1-independent PI3Kinase Activation Causing Imatinib-Resistance

Journal of Hematology and Oncology

English

Clinical and Genetic Studies of ETV6/ABL1-positive Chronic Myeloid Leukaemia in Blast Crisis Treated With Imatinib Mesylate

British Journal of Haematology

Hematology

2003

English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

English

Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up

English

Gynaecomastia in Men With Chronic Myeloid Leukaemia After Imatinib

The Lancet

Medicine

2003

English

Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing During Imatinib Mesylate Therapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Piyush Rajbhandari

The Use of Imatinib Resistance Mutation Analysis to Direct Therapy in Philadelphia Chromosome/BCR-Abl1 Positive Chronic Myeloid Leukaemia Patients Failing Imatinib Treatment, in Patan Hospital, Nepal

Related publications

Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients

BCR-ABL1 Mutations in Patients With Imatinib-Resistant Philadelphia Chromosome-Positive Leukemia by Use of the PCR-Invader Assay

Prognostic Significance of Micro RNA 150 Marker in BCR-ABL Positive Chronic Myeloid Leukaemia Patients on Imatinib Mesylate

BCR-ABL1-independent PI3Kinase Activation Causing Imatinib-Resistance

Clinical and Genetic Studies of ETV6/ABL1-positive Chronic Myeloid Leukaemia in Blast Crisis Treated With Imatinib Mesylate

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up

Gynaecomastia in Men With Chronic Myeloid Leukaemia After Imatinib

Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing During Imatinib Mesylate Therapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase